A recent trial of chemo-radiation with S-1 against gastric cancer

Yoshiro Saikawa, Tsuyoshi Kiyota, Rieko Nakamura, Norihito Wada, Masashi Yoshida, Tetsuro Kubota, Koichiro Kumai, Naoyuki Shigematsu, Atsushi Kubo, Masaki Kitajima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A recent development of novel anticancer agents like S-1, CPT-11 or taxanes has improved a therapeutic outcome for advanced gastric cancer, while conventional anticancer agents showed less anticancer effect against gastric cancer. The present main drug in Japan is S-1, which is easily used for outpatient with a high efficacy rate and low toxicity, also shows better effect in combination with other anticancer drugs than S-1 alone. In the present article, we demonstrated significant meaning of additional radiation therapy with anticancer drugs like S-1. With novel anticancer drugs like S-1, we will expose a clinical advantage and appropriateness for chemo-radiation therapy against gastric cancer discussed in the present references according to chemo-radiation therapy. Although chemo-radiation therapy has been recognized as one of the standard therapies for gastric cancer in Western countries, radiation therapy was selected in Japan for palliation therapy of recurrent disease or a terminal cancer to improve patients' QOL. On the other hand, we demonstrated in our trial of chemo-radiation therapy with S-1/low-dose CDDP/radiation (TSLDR), which was applied to initial treatment against highly advanced Stage IV gastric cancer and revealed the usefulness of the regimen in anticancer effect and toxicity. In addition, chemo-radiation therapy including novel anticancer agents like S-1 will be discussed based on various kinds of view points, expecting a better clinical outcome of multimodal therapies against advanced gastric cancer.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy.
Volume33 Suppl 1
Publication statusPublished - 2006 Jun

Fingerprint

Stomach Neoplasms
Radiotherapy
Radiation
Antineoplastic Agents
irinotecan
Pharmaceutical Preparations
Japan
Therapeutics
Taxoids
Outpatients
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Saikawa, Y., Kiyota, T., Nakamura, R., Wada, N., Yoshida, M., Kubota, T., ... Kitajima, M. (2006). A recent trial of chemo-radiation with S-1 against gastric cancer. Gan to kagaku ryoho. Cancer & chemotherapy., 33 Suppl 1, 99-105.

A recent trial of chemo-radiation with S-1 against gastric cancer. / Saikawa, Yoshiro; Kiyota, Tsuyoshi; Nakamura, Rieko; Wada, Norihito; Yoshida, Masashi; Kubota, Tetsuro; Kumai, Koichiro; Shigematsu, Naoyuki; Kubo, Atsushi; Kitajima, Masaki.

In: Gan to kagaku ryoho. Cancer & chemotherapy., Vol. 33 Suppl 1, 06.2006, p. 99-105.

Research output: Contribution to journalArticle

Saikawa, Y, Kiyota, T, Nakamura, R, Wada, N, Yoshida, M, Kubota, T, Kumai, K, Shigematsu, N, Kubo, A & Kitajima, M 2006, 'A recent trial of chemo-radiation with S-1 against gastric cancer', Gan to kagaku ryoho. Cancer & chemotherapy., vol. 33 Suppl 1, pp. 99-105.
Saikawa, Yoshiro ; Kiyota, Tsuyoshi ; Nakamura, Rieko ; Wada, Norihito ; Yoshida, Masashi ; Kubota, Tetsuro ; Kumai, Koichiro ; Shigematsu, Naoyuki ; Kubo, Atsushi ; Kitajima, Masaki. / A recent trial of chemo-radiation with S-1 against gastric cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2006 ; Vol. 33 Suppl 1. pp. 99-105.
@article{6f2e93c02142462693c654dad8d2d5d9,
title = "A recent trial of chemo-radiation with S-1 against gastric cancer",
abstract = "A recent development of novel anticancer agents like S-1, CPT-11 or taxanes has improved a therapeutic outcome for advanced gastric cancer, while conventional anticancer agents showed less anticancer effect against gastric cancer. The present main drug in Japan is S-1, which is easily used for outpatient with a high efficacy rate and low toxicity, also shows better effect in combination with other anticancer drugs than S-1 alone. In the present article, we demonstrated significant meaning of additional radiation therapy with anticancer drugs like S-1. With novel anticancer drugs like S-1, we will expose a clinical advantage and appropriateness for chemo-radiation therapy against gastric cancer discussed in the present references according to chemo-radiation therapy. Although chemo-radiation therapy has been recognized as one of the standard therapies for gastric cancer in Western countries, radiation therapy was selected in Japan for palliation therapy of recurrent disease or a terminal cancer to improve patients' QOL. On the other hand, we demonstrated in our trial of chemo-radiation therapy with S-1/low-dose CDDP/radiation (TSLDR), which was applied to initial treatment against highly advanced Stage IV gastric cancer and revealed the usefulness of the regimen in anticancer effect and toxicity. In addition, chemo-radiation therapy including novel anticancer agents like S-1 will be discussed based on various kinds of view points, expecting a better clinical outcome of multimodal therapies against advanced gastric cancer.",
author = "Yoshiro Saikawa and Tsuyoshi Kiyota and Rieko Nakamura and Norihito Wada and Masashi Yoshida and Tetsuro Kubota and Koichiro Kumai and Naoyuki Shigematsu and Atsushi Kubo and Masaki Kitajima",
year = "2006",
month = "6",
language = "English",
volume = "33 Suppl 1",
pages = "99--105",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

}

TY - JOUR

T1 - A recent trial of chemo-radiation with S-1 against gastric cancer

AU - Saikawa, Yoshiro

AU - Kiyota, Tsuyoshi

AU - Nakamura, Rieko

AU - Wada, Norihito

AU - Yoshida, Masashi

AU - Kubota, Tetsuro

AU - Kumai, Koichiro

AU - Shigematsu, Naoyuki

AU - Kubo, Atsushi

AU - Kitajima, Masaki

PY - 2006/6

Y1 - 2006/6

N2 - A recent development of novel anticancer agents like S-1, CPT-11 or taxanes has improved a therapeutic outcome for advanced gastric cancer, while conventional anticancer agents showed less anticancer effect against gastric cancer. The present main drug in Japan is S-1, which is easily used for outpatient with a high efficacy rate and low toxicity, also shows better effect in combination with other anticancer drugs than S-1 alone. In the present article, we demonstrated significant meaning of additional radiation therapy with anticancer drugs like S-1. With novel anticancer drugs like S-1, we will expose a clinical advantage and appropriateness for chemo-radiation therapy against gastric cancer discussed in the present references according to chemo-radiation therapy. Although chemo-radiation therapy has been recognized as one of the standard therapies for gastric cancer in Western countries, radiation therapy was selected in Japan for palliation therapy of recurrent disease or a terminal cancer to improve patients' QOL. On the other hand, we demonstrated in our trial of chemo-radiation therapy with S-1/low-dose CDDP/radiation (TSLDR), which was applied to initial treatment against highly advanced Stage IV gastric cancer and revealed the usefulness of the regimen in anticancer effect and toxicity. In addition, chemo-radiation therapy including novel anticancer agents like S-1 will be discussed based on various kinds of view points, expecting a better clinical outcome of multimodal therapies against advanced gastric cancer.

AB - A recent development of novel anticancer agents like S-1, CPT-11 or taxanes has improved a therapeutic outcome for advanced gastric cancer, while conventional anticancer agents showed less anticancer effect against gastric cancer. The present main drug in Japan is S-1, which is easily used for outpatient with a high efficacy rate and low toxicity, also shows better effect in combination with other anticancer drugs than S-1 alone. In the present article, we demonstrated significant meaning of additional radiation therapy with anticancer drugs like S-1. With novel anticancer drugs like S-1, we will expose a clinical advantage and appropriateness for chemo-radiation therapy against gastric cancer discussed in the present references according to chemo-radiation therapy. Although chemo-radiation therapy has been recognized as one of the standard therapies for gastric cancer in Western countries, radiation therapy was selected in Japan for palliation therapy of recurrent disease or a terminal cancer to improve patients' QOL. On the other hand, we demonstrated in our trial of chemo-radiation therapy with S-1/low-dose CDDP/radiation (TSLDR), which was applied to initial treatment against highly advanced Stage IV gastric cancer and revealed the usefulness of the regimen in anticancer effect and toxicity. In addition, chemo-radiation therapy including novel anticancer agents like S-1 will be discussed based on various kinds of view points, expecting a better clinical outcome of multimodal therapies against advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=33747445497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747445497&partnerID=8YFLogxK

M3 - Article

C2 - 16897982

AN - SCOPUS:33747445497

VL - 33 Suppl 1

SP - 99

EP - 105

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

ER -